The Role of DPP4 Activity in Cardiovascular Districts: In Vivo and In Vitro Evidence
The introduction of incretin hormone-based therapies represents a novel therapeutic strategy, since these drugs not only improve glycemia with minimal risk of hypoglycemia, but also have other extraglycemic beneficial effects. These agents, which are effective in improving glucose control, could als...
Saved in:
| Main Authors: | L. Pala, C. M. Rotella |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2013/590456 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection
by: Francisco Epelde
Published: (2024-11-01) -
Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studies
by: Jérémie Decalf, et al.
Published: (2016-04-01) -
Screening Emodin Derivatives as DPP-4 Inhibitor Candidates: In Silico and In Vitro Assessment
by: Dina Azkiyah, et al.
Published: (2025-05-01) -
NeSyDPP-4: discovering DPP-4 inhibitors for diabetes treatment with a neuro-symbolic AI approach
by: Delower Hossain, et al.
Published: (2025-07-01) -
DPP4 rs17574 polymorphism and elevated DPP4 levels linked to fatty liver in subclinical atherosclerosis: GEA study findings
by: Gilberto Vargas-Alarcón, et al.
Published: (2025-04-01)